Why Arrowhead Pharmaceuticals Is Drawing Investor Attention Now Arrowhead Pharmaceuticals (ARWR) is back on many watchlists after a sharp total return over the past 3 months and the past year. This ...
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its ...
Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results